Literature DB >> 20557268

Rationalization and prediction of in vivo metabolite exposures: the role of metabolite kinetics, clearance predictions and in vitro parameters.

Justin D Lutz1, Yasushi Fujioka, Nina Isoherranen.   

Abstract

IMPORTANCE OF THE FIELD: Due to growing concerns over toxic or active metabolites, significant efforts have been focused on qualitative identification of potential in vivo metabolites from in vitro data. However, limited tools are available to quantitatively predict their human exposures. AREAS COVERED IN THIS REVIEW: Theory of clearance predictions and metabolite kinetics is reviewed together with supporting experimental data. In vitro and in vivo data of known circulating metabolites and their parent drugs were collected and the predictions of in vivo exposures of the metabolites were evaluated. WHAT THE READER WILL GAIN: The theory and data reviewed will be useful in early identification of human metabolites that will circulate at significant levels in vivo and help in designing in vivo studies that focus on characterization of metabolites. It will also assist in rationalization of metabolite-to-parent ratios used as markers of specific enzyme activity. TAKE HOME MESSAGE: The relative importance of a metabolite in comparison to the parent compound as well as other metabolites in vivo can only be predicted using the metabolite's in vitro formation and elimination clearances, and the in vivo disposition of a metabolite can only be rationalized when the elimination pathways of that metabolite are known.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20557268      PMCID: PMC2923241          DOI: 10.1517/17425255.2010.497487

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  45 in total

1.  Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes.

Authors:  R S Obach
Journal:  Drug Metab Dispos       Date:  1999-11       Impact factor: 3.922

2.  Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes.

Authors:  Kiyomi Ito; J Brian Houston
Journal:  Pharm Res       Date:  2004-05       Impact factor: 4.200

3.  Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance.

Authors:  Dermot F McGinnity; Matthew G Soars; Richard A Urbanowicz; Robert J Riley
Journal:  Drug Metab Dispos       Date:  2004-07-30       Impact factor: 3.922

Review 4.  Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes.

Authors:  D S Streetman; J S Bertino; A N Nafziger
Journal:  Pharmacogenetics       Date:  2000-04

5.  Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes.

Authors:  A Abelö; T B Andersson; M Antonsson; A K Naudot; I Skånberg; L Weidolf
Journal:  Drug Metab Dispos       Date:  2000-08       Impact factor: 3.922

6.  Kinetic considerations relating to the accrual and elimination of drug metabolites.

Authors:  A J Cummings; B K Martin; G S Park
Journal:  Br J Pharmacol Chemother       Date:  1967-02

7.  In-vivo indices of CYP2D6 activity: comparison of dextromethorphan metabolic ratios in 4-h urine and 3-h plasma.

Authors:  J Chládek; G Zimová; M Beránek; J Martínková
Journal:  Eur J Clin Pharmacol       Date:  2000-12       Impact factor: 2.953

8.  Effects of allicin on CYP2C19 and CYP3A4 activity in healthy volunteers with different CYP2C19 genotypes.

Authors:  Li-Jun Yang; Lan Fan; Zhao-Qian Liu; Yan-Mei Mao; Dong Guo; Li-Hui Liu; Zhi-Rong Tan; Liang Peng; Chun-Ting Han; Dong-Li Hu; Dan Wang; Hong-Hao Zhou
Journal:  Eur J Clin Pharmacol       Date:  2009-01-27       Impact factor: 2.953

9.  Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes.

Authors:  P C Ho; F S Abbott; U M Zanger; T K H Chang
Journal:  Pharmacogenomics J       Date:  2003       Impact factor: 3.550

10.  Atomoxetine hydrochloride: clinical drug-drug interaction prediction and outcome.

Authors:  John-Michael Sauer; Amanda J Long; Barbara Ring; Jennifer S Gillespie; Nathan P Sanburn; Karl A DeSante; David Petullo; Mark R VandenBranden; Charles B Jensen; Steven A Wrighton; Brian P Smith; Holly A Read; Jennifer W Witcher
Journal:  J Pharmacol Exp Ther       Date:  2003-11-10       Impact factor: 4.030

View more
  9 in total

1.  Allosteric activation of cytochrome P450 3A4 by α-naphthoflavone: branch point regulation revealed by isotope dilution analysis.

Authors:  Caleb M Woods; Cristina Fernandez; Kent L Kunze; William M Atkins
Journal:  Biochemistry       Date:  2011-10-28       Impact factor: 3.162

2.  Prediction of relative in vivo metabolite exposure from in vitro data using two model drugs: dextromethorphan and omeprazole.

Authors:  Justin D Lutz; Nina Isoherranen
Journal:  Drug Metab Dispos       Date:  2011-10-18       Impact factor: 3.922

3.  An S-warfarin and AZD1981 interaction: in vitro and clinical pilot data suggest the N-deacetylated amino acid metabolite as the primary perpetrator.

Authors:  Ken Grime; Rikard Pehrson; Pär Nordell; Michael Gillen; Wolfgang Kühn; Timothy Mant; Marie Brännström; Petter Svanberg; Barry Jones; Clive Brealey
Journal:  Br J Clin Pharmacol       Date:  2016-10-13       Impact factor: 4.335

Review 4.  Current Therapeutic Landscape and Safety Roadmap for Targeting the Aryl Hydrocarbon Receptor in Inflammatory Gastrointestinal Indications.

Authors:  Samantha C Faber; Tejas S Lahoti; Ewan R Taylor; Lauren Lewis; Jessica M Sapiro; Vicencia Toledo Sales; Yvonne P Dragan; Brandon D Jeffy
Journal:  Cells       Date:  2022-05-21       Impact factor: 7.666

5.  Chiral Plasma Pharmacokinetics and Urinary Excretion of Bupropion and Metabolites in Healthy Volunteers.

Authors:  Andrea R Masters; Brandon T Gufford; Jessica Bo Li Lu; Ingrid F Metzger; David R Jones; Zeruesenay Desta
Journal:  J Pharmacol Exp Ther       Date:  2016-06-02       Impact factor: 4.030

6.  Comprehensive interpretation of in vitro micronucleus test results for 292 chemicals: from hazard identification to risk assessment application.

Authors:  Byron Kuo; Marc A Beal; John W Wills; Paul A White; Francesco Marchetti; Andy Nong; Tara S Barton-Maclaren; Keith Houck; Carole L Yauk
Journal:  Arch Toxicol       Date:  2022-04-21       Impact factor: 6.168

7.  Quantitative Prediction of Drug-Drug Interactions Involving Inhibitory Metabolites in Drug Development: How Can Physiologically Based Pharmacokinetic Modeling Help?

Authors:  I E Templeton; Y Chen; J Mao; J Lin; H Yu; S Peters; M Shebley; M V Varma
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-09-19

8.  The effect of grape seed and green tea extracts on the pharmacokinetics of imatinib and its main metabolite, N-desmethyl imatinib, in rats.

Authors:  Ruba S Darweesh; Tamam El-Elimat; Aref Zayed; Tareq N Khamis; Wahby M Babaresh; Tawfiq Arafat; Ahmed H Al Sharie
Journal:  BMC Pharmacol Toxicol       Date:  2020-11-16       Impact factor: 2.483

9.  Metabolite Profiling and Characterization of LW6, a Novel HIF-1α Inhibitor, as an Antitumor Drug Candidate in Mice.

Authors:  Kiho Lee; Ji-Yoon Lee; Kyeong Lee; Cho-Rock Jung; Min Ju Kim; Jung Ah Kim; Dong Gu Yoo; Eun Jin Shin; Soo Jin Oh
Journal:  Molecules       Date:  2021-03-30       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.